UGN-102治疗复发性低级别中危非肌层浸润性膀胱癌:3期ENVISION试验24个月缓解持续时间结果
ENVISION是一项正在进行的多国单臂3期研究,纳入240例活检证实的复发性低级别中危非肌层浸润性膀胱癌患者,接受6次每周一次膀胱内UGN-102灌注。3个月时191例(80%;95%CI:74-85)达完全缓解,完全缓解后24个月无事件生存概率为72%(95%CI:64-79;Kaplan-Meier估计),≥10%患者出现排尿困难。
要点
- UGN-102膀胱内灌注后3个月完全缓解率达80%(95%CI:74-85)。
- 完全缓解者24个月无事件生存概率为72%(95%CI:64-79)。
- 常见不良事件为排尿困难,发生率≥10%。
核心结论
- UGN-102治疗后达完全缓解的患者24个月后保持无事件概率高,提示其作为非手术治疗可提供持久完全缓解。
研究设计与样本
- ENVISION为正在进行的多国单臂3期研究,纳入240例活检证实的复发性低级别中危非肌层浸润性膀胱癌患者,接受6次每周一次膀胱内UGN-102灌注。
主要发现
- 3个月时191例(80%;95%CI:74-85)达完全缓解。
- 完全缓解者中,完全缓解后24个月无事件概率为72%(95%CI:64-79;Kaplan-Meier估计)。
- 191例完全缓解者中36例出现低级别疾病复发。
- 240例入组患者中发生率≥10%的治疗中出现的不良事件为排尿困难。
临床怎么用
- 对于复发性低级别中危非肌层浸润性膀胱癌,UGN-102可作为非手术选择,治疗后3个月评估完全缓解并长期随访。
局限性
- 单臂设计。
- 患者种族多样性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We report the duration of response to UGN-102 treatment in patients with recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer (LG-IR-NMIBC) 24 months after achieving complete response (CR). MATERIALS AND METHODS: ENVISION is an ongoing, multinational, single-arm, phase 3 study in patients with biopsy-proven recurrent LG-IR-NMIBC. Patients received 6 once-weekly intravesical instillations of UGN-102. Patients underwent cystoscopy, urine cytology testing, and for-cause biopsy to determine bladder cancer presence at 3 months. Duration of response (from CR at 3 months to disease recurrence, progression, or death from any cause) at 24 months was estimated using the Kaplan-Meier method. RESULTS: A total of 240 patients were enrolled and received ≥ 1 dose of UGN-102. Most patients were White (98%), male (61%), and aged ≥ 65 years (68%). At 3 months, 191 patients (80%; 95% CI: 74-85) achieved CR. Among these responders, the probability of remaining event-free 24 months after CR was 72% (95% CI: 64-79; Kaplan-Meier estimate). Among patients with CR at 3 months (n = 191), 36 developed low-grade disease recurrence. A treatment-emergent adverse event that occurred in ≥ 10% of enrolled patients (N = 240) was dysuria. CONCLUSIONS: Patients who achieved CR after UGN-102 treatment had a high probability of remaining event-free 24 months later. These data indicate that UGN-102 is a novel, nonsurgical treatment that provides a durable CR for patients with recurrent LG-IR-NMIBC. Study limitations included the single-arm design and the limited racial diversity of the patients. TRIAL REGISTRATION: ClinicalTrials.gov: NCT05243550.
引用
- Prasad SM, Shishkov D, Mihaylov NV, et al. UGN-102 for Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial. J Urol. 2026. PMID: 41880645. doi:10.1097/JU.0000000000005041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。